Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine in Pulmonary Arterial Hypertension
NCT04528056Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminosalicylic acid + sulphasalazine in pulmonary arterial hypertension (PAH), sponsored by Renji Hospital. Status: unknown.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04528056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528056.